Hypercoagulable States and New Anticoagulants, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Authors :
Mark Crowther & Marco Donadini
Date of Publication: 09/2010
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for ...view more
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.
Author Information
By Mark Crowther, MD, MSc, FRCPC and Marco Donadini, MD
https://www.uk.elsevierhealth.com/hypercoagulable-states-and-new-anticoagulants-an-issue-of-hematologyoncology-clinics-of-north-america-9781437725292.html84902Hypercoagulable States and New Anticoagulants, An Issue of Hematology/Oncology Clinics of North Americahttps://www.uk.elsevierhealth.com/media/catalog/product/9/7/9781437725292_6.jpg47.2462.99GBPInStock/Medicine and Surgery/Haematology/Books/Clinics Review Articles100335255039561283917453100005145120This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients. This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.00add-to-cart97814377252922011 and earlierProfessionalBy Mark Crowther, MD, MSc, FRCPC and Marco Donadini, MD20101Book152w x 229h (6.00" x 9.00")Saunders014 Sep 2010PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 10 DAYSBy <STRONG>Mark Crowther</STRONG>, MD, MSc, FRCPC and <STRONG>Marco Donadini</STRONG>, MDClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
